Name | Value |
---|---|
Revenues | 204.7M |
Cost of Revenue | 53.3M |
Gross Profit | 151.5M |
Operating Expense | 42.2M |
Operating I/L | 109.2M |
Other Income/Expense | -13.4M |
Interest Income | 2.3M |
Pretax | 95.9M |
Income Tax Expense | 8.4M |
Net Income/Loss | 87.4M |
Maravai LifeSciences Holdings, Inc. is a leading life sciences company that provides essential products for drug therapy development, diagnostics, and vaccine research. The company operates in two segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on manufacturing and selling products for gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. The Biologics Safety Testing segment offers analytical products for biologic manufacturing process development. Maravai serves biopharmaceutical companies, life sciences research firms, academic institutions, and in vitro diagnostics companies, generating revenue through the sale of nucleic acids, antibody-based products, and biologics safety testing solutions.